Bosera Szse Chinext Daily (2x) Leveraged Product(07234.HK) Fell 4.99% to 11.610 HKD
Newtimespace News, as of 15:58 on May 21, Bosera Szse Chinext Daily (2x) Leveraged Product(07234.HK) was quoted at HKD 11.610, down 4.99%. The ETF opened at HKD 12.400, with a high of HKD 12.890 and a low of HKD 11.550. The latest Net Asset Value (NAV) per unit is HKD 12.304, with a premium rate of -0.69%. The asset size is approximately HKD 213 million.
Bosera Szse Chinext Daily (2x) Leveraged Product(07234.HK) is a leveraged and inverse product issued by Bosera Funds (International) Co., Limited. It aims to provide, before fees and expenses, investment returns that correspond to twice (2x) the daily performance of the ChiNext Index. The ChiNext Index is compiled by the Shenzhen Stock Exchange and consists of the stocks of 100 listed companies on the ChiNext board with large market capitalization and good liquidity. It reflects the operation of the ChiNext market. Its constituents are mostly concentrated in high-growth, high-tech industries such as electrical equipment and pharmaceuticals & biotechnology.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- DETAI NEWENERGY (00559.HK): Enters Memorandum of Understanding for Proposed Acquisition of HKD 505 Million; Trading Remains Suspended
- SCIENTECH (02291.HK): Acquires 54.2384% Equity of Shanghai Minwei Biotechnology for RMB 1.088 Billion, Constituting Major and Connected Transaction
- CHINAHONGQIAO (01378.HK): Revises Annual Caps under Industrial Products Purchase Agreement, 2027 Cap Raised to RMB 26.24 Million